POM-V Prescription Required

Bovilis IBR Marker Live, Lyophilisate and Solvent for Suspension for Cattle

Active ingredient: Infectious bovine rhinotraceitis virus

Form

Drops

Species

Cattle

Manufacturer

Intervet International B.V.

VMD MA No.

06376/3022

What it's used for

Onset of immunity: An increase in immunity was demonstrated 4 days after intranasal vaccination and 14 days after intramuscular vaccination of 3 month old...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Infectious bovine rhinotrace...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bovilis IBR Marker Live, Lyophilisate and Solvent for Suspension for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Onset of immunity:
An increase in immunity was demonstrated 4 days after intranasal vaccination and
14 days after intramuscular vaccination of 3 month old seronegative animals.
Duration of immunity:
After intranasal administration to 2 week old calves immunity lasts at least until the
age of 3-4 months. In the presence of maternally derived antibodies, the protection
of the vaccine may not be complete until a second vaccination. This second
vaccination should be administered at 3-4 months of age and will result in protective
immunity that lasts for at least 6 months.
Single intranasal or intramuscular vaccination of 3 month old animals provides
protective immunity (reduction of clinical signs and reduction of viral excretion),
which was demonstrated via challenge 3 weeks after vaccination. Reduction of viral
excretion is maintained for at least 6 months after single vaccination.
Revaccination to ensure protection after the initial 6 months protection period has
elapsed will result in protective immunity that lasts for 1 year.
Specific information:
No information is available on the efficacy of the vaccine to prevent a latent wild virus
infection or to prevent wild virus re-excretion in the latent carrier.

Method of administration:
- from the age of 3 months onwards: intranasal use or intramuscular use.
- at an age between 2 weeks and 3 months: intranasal use.
For intranasal use (1 ml in each nostril), the use of a nozzle is recommended.
Primary vaccination:
- Basic vaccination:
Vaccinate each animal from 3 months of age onwards with one single dose.
- Early protection schedule:
When the first vaccination is given between the age of 2 weeks and 3 months, a
second vaccination should be given at an age of 3-4 months.
First revaccination:
The first revaccination should be given 6 months after primary vaccination. Bovilis
IBR Marker Inac can alternatively be used for this revaccination.
Subsequent revaccinations:
All following revaccinations should be given at an interval no greater than 12 months.
Bovilis IBR Marker Inac can alternatively be used for these revaccinations.
The product literature of Bovilis IBR Marker Inac should be consulted before using it
for revaccination.
For revaccination, the lyophilisate may be reconstituted shortly before use with
Bovilis BVD for use in cattle from 15 months of age (i.e. those that have previously
been vaccinated separately with Bovilis IBR Marker Live and Bovilis BVD). The
following instructions should be used:
Bovilis IBR Marker Live Bovilis BVD
5 doses + 10 ml
10 doses + 20 ml
25 doses + 50 ml
50 doses + 100 ml
A single dose (2 ml) of Bovilis IBR Marker Live mixed with Bovilis BVD is given
intramuscularly.
Shelf life after mixing with Bovilis BVD: 3 hours.
Use sterile vaccination equipment free from disinfectants. To prevent the spread of
any infective agents the intranasal equipment should be changed at each animal.
Visual appearance after reconstitution:
- In solvent: colourless to slightly opaque suspension.
- In Bovilis BVD: as specified in the product information for Bovilis BVD alone.

None.

Cattle:
Common
(1 to 10 animals / 100 animals
treated):
Elevated temperature
, Nasal discharge
.Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Hypersensitivity reaction.
A rise of 1 C may occur up to 5 days post vaccination.
After intranasal vaccination.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Vaccinate healthy animals only.
The presence of maternal antibodies can influence the efficacy of the vaccination.
Therefore, it is recommended to ascertain the immune status of calves before
vaccination is started.

Special precautions for safe use in the target species:
After intranasal administration, the vaccine virus can spread to in-contact cattle.
Cattle which need to remain totally free from BHV-1 antibodies should be separated
from intranasally vaccinated animals.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

Safety and efficacy data - in cattle from 3 weeks of age onwards - are available
which demonstrate that this vaccine can be administered on the same day but not
mixed with Bovilis Bovipast RSP.
Safety and efficacy data are available which demonstrate that for the intramuscular
revaccination - in cattle from 15 months of age onwards (i.e. those that have
previously been vaccinated separately with Bovilis IBR Marker Live and Bovilis BVD)
- this vaccine can be mixed and administered with Bovilis BVD. The product
literature of Bovilis BVD should be consulted before administration of the mixed
products. The adverse effects observed after administration of one dose or an
overdose of the mixed vaccines are not different from those described for the
vaccines administered separately.
When mixed with Bovilis BVD at revaccination, the demonstrated efficacy claims for
Bovilis IBR Marker Live are as follows:
-
BHV-1 and to reduce nasal excretion of field virus.
-
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the products mentioned above.
A decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case by case basis.
Do not use together with immunosuppressive agents.

Lyophilisate:
Store in a refrigerator (2 C – 8 C).
Do not freeze.
Protect from light.
Solvent:
Store below 25 C if stored independently from the lyophilisate.
Do not freeze.

Zero days.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.